Baseline characteristics of the study population
| Characteristic . | N (%)/median (range) . |
|---|---|
| Age, y | |
| Median age | 36 (18-70) |
| ≥ 60 | 2 (9) |
| ALL subtype | |
| T-cell ALL | 10 (45) |
| B-cell ALL | 12 (55) |
| Ph-like | 6/12 (50) |
| ECOG performance status | |
| 0 | 4 (18) |
| 1 | 15 (68) |
| 2 | 3 (14) |
| Isolated extramedullary disease | 3 (14) |
| Baseline blood parameters | |
| White blood cells, ×109/L | 6.9 (0.1-143.3) |
| Hemoglobin, g/dL | 10.4 (7.1-13.9) |
| Platelets, ×109/L | 35 (6-205) |
| Bone marrow blasts, % | 83 (0-97) |
| Cytogenetics | |
| Diploid | 8 (36) |
| Complex | 5 (23) |
| Miscellaneous | 7 (32) |
| Insufficient metaphases/not done | 2 (9) |
| Prior venetoclax | 1 (5) |
| Prior alloSCT | 6 (27) |
| Prior therapies (B-cell ALL) | |
| Median prior lines of therapy | 3 (1-6) |
| Prior INO | 9/12 (75) |
| Prior Blina | 12/12 (100) |
| Prior INO and Blina | 9/12 (75) |
| Prior CD19 CAR T cells | 9/12 (75) |
| Prior therapies (T-cell ALL) | |
| Median prior lines of therapies | 2 (1-4) |
| Prior nelarabine | 5/10 (50) |
| Characteristic . | N (%)/median (range) . |
|---|---|
| Age, y | |
| Median age | 36 (18-70) |
| ≥ 60 | 2 (9) |
| ALL subtype | |
| T-cell ALL | 10 (45) |
| B-cell ALL | 12 (55) |
| Ph-like | 6/12 (50) |
| ECOG performance status | |
| 0 | 4 (18) |
| 1 | 15 (68) |
| 2 | 3 (14) |
| Isolated extramedullary disease | 3 (14) |
| Baseline blood parameters | |
| White blood cells, ×109/L | 6.9 (0.1-143.3) |
| Hemoglobin, g/dL | 10.4 (7.1-13.9) |
| Platelets, ×109/L | 35 (6-205) |
| Bone marrow blasts, % | 83 (0-97) |
| Cytogenetics | |
| Diploid | 8 (36) |
| Complex | 5 (23) |
| Miscellaneous | 7 (32) |
| Insufficient metaphases/not done | 2 (9) |
| Prior venetoclax | 1 (5) |
| Prior alloSCT | 6 (27) |
| Prior therapies (B-cell ALL) | |
| Median prior lines of therapy | 3 (1-6) |
| Prior INO | 9/12 (75) |
| Prior Blina | 12/12 (100) |
| Prior INO and Blina | 9/12 (75) |
| Prior CD19 CAR T cells | 9/12 (75) |
| Prior therapies (T-cell ALL) | |
| Median prior lines of therapies | 2 (1-4) |
| Prior nelarabine | 5/10 (50) |
alloSCT, allogeneic stem cell transplantation; Blina, blinatumomab; CAR T-cells, chimeric antigen receptor T cells; ECOG, Eastern Cooperative Oncology Group; Ph-like, Philadelphia-like.